News and Events

Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products. The investment reinforces Halo Pharma’s position as a reliable partner for both development and commercial manufacturing as it allows for seamless scale up from Halo Whippany’s Gerties Mini-Pactor® currently used for development, clinical and small scall commercial manufacturing. The Macro-Pactor is expected to be online in the first quarter of 2026. Its high throughput, superior dry-granulation performance, improved powder flow, and reduced variability will significantly expand Halo Pharma’s dry-granulation capabilities. It will improve formulation flexibility, process predictability, and granule quality. This technology is especially beneficial for the development of moisture-sensitive APIs, high-drug-load formulations, poor-flowing powders, potent compounds, and modified-release products within Halo Pharma’s portfolio. “One of the major advantages of adding the Macro-Pactor is that the process parameters established during

Whippany, NJ – October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will oversee the operations of the Halo Mirabel cGMP manufacturing site Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, has appointed Laurent Malgouyres as Site Director for its cGMP facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance. Malgouyres has worked in the pharmaceutical industry for over 14 years, most recently serving as Vice President of Operations at Omega Laboratories/Juno Pharmaceuticals in Canada. His previous work leadership roles include positions at Pharmascience, where he managed FDA- and Health Canada-approved sites that employed more than 200 people. Throughout his career, he has successfully led initiatives to increase production capacity, implement operational efficiency processes, and execute major capital investment projects. “Laurent has a track record of establishing autonomous, high-performing teams while fostering a culture of operational excellence, continuous improvement, and human development that align with our core beliefs and objectives at Halo Pharma,” says Lee Karras, CEO of Noramco, parent company of Halo Pharma. “Laurent’s experience and vision will be instrumental as we continue to

Woodstock, IL, August 12, 2025  Bender brings 35 years of pharmaceutical industry experience to dual role Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), and Halo Pharma, a leading CDMO specializing in pharmaceutical services, have named John Bender as the new Vice President of Business Development for the two organizations. Bender is a 35-year veteran of the pharmaceutical industry and brings deep expertise in CDMO services to his new role. He joins the organization from Alvogen Pharmaceuticals, where he most recently served as Vice President of U.S. Third Party Operations, overseeing CDMO strategic sourcing for North America. Prior to that, he was Vice President of Business Development for Alvogen’s Norwich Pharma CDMO Services division. “John’s extensive experience in the CDMO sector—not only in sales but also as a buyer of CDMO services—along with his proven track record of building long-term partnerships comes at a great time as we look to launch sterile filling services out of Halo and grow our blow-fill-seal business as we expand our bottle packaging operations at Woodstock,” said Lee Karras, Executive Chairman. John will be based in Illinois and lead sales and marketing efforts across Woodstock Sterile Solutions and Halo Pharma,

WILMINGTON, Del. and WHIPPANY, New High-Speed Filling Line to Support Growing Demand for Sterile Injectables and Strengthen Domestic Supply Chain Learn More About Halo Pharma’s New Sterile Manufacturing Capabilities at DCAT Week 2025 The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, today announced a $25 million investment in its Halo Pharma facility in Whippany, New Jersey, to establish sterile injectable manufacturing capabilities, including ready-to-use, syringe, cartridge, and vial filling. This expansion aims to address critical capacity shortages in the US injectable supply chain and meet the growing demand from pharmaceutical companies seeking reliable domestic sterile manufacturing partners. The investment includes the installation of a high-speed, state-of-the-art Groninger UFVN FlexFill syringe, cartridge, and vial filling line and a SKAN isolator to enhance production efficiency and regulatory compliance. The new capabilities will allow Halo Pharma to manufacture batches ranging from 5,000 to 250,000 units, with an annual production capacity exceeding 50 million units. The initial container systems will include 0.5 mL, 1 mL long, and 1 mL short syringes, along with 2R vials, all in ready-to-fill formats. Container filling can be performed via peristaltic pump or vacuum. Additional syringe, cartridge, and vial options